Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led ...

Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries Recently completed Phase 1 Single Ascending Dose study of PRO-203 in healthy ...
KXAN

Nordic Bioscience announces PRO-C3 launched by Roche Diagnostics on cobas analysers

HERLEV, Denmark , May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT ...